Anivive

Overview
News
Animal Therapeutics?
Product stageSegments
Seed
?
Next-generation vaccines and drugs
?

Anivive Lifesciences is a pet health technology company dedicated to solving unmet needs in the veterinary community. They focus on developing novel therapeutics, biologics, and vaccines for three critical areas: oncology, anti-virals, and anti-fungal treatments. Anivive's proprietary software platform leverages artificial intelligence, biotech, and veterinary medicine to accelerate the discovery and development of new, affordable treatments for life-threatening diseases in pets.

In October 2023, Anivive announced the successful completion of clinical trials for what is poised to be the world's first fungal vaccine for animals, offering effective protection against Valley Fever. This groundbreaking vaccine aims to address a significant unmet need, as over 30 million dogs reside in Valley Fever hotspots, and pet owners in California and Arizona have faced skyrocketing treatment costs surpassing USD 200 million as of August 2023.

Anivive has also achieved notable milestones in other areas of its pipeline. In January 2022, the company licensed Laverdia-CA1, a novel oral treatment for canine lymphoma, to Dechra Pharmaceuticals PLC for sales and distribution. Laverdia-CA1 represents a convenient and cost-effective option for pet owners to pursue cancer treatment for their dogs.

Additionally, in December 2022, Anivive received the prestigious "Best Animal Health Company of the Year" award from S&P Global's Head of Animal Health for its significant growth, innovation, and ability to successfully develop and monetize products across various unmet needs.


Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
3777 Worsham Ave Ste 200 Long Beach CA USA
Founded year:
2015
Employees:
11-50
IPO status:
Private
Total funding:
USD 44.8 mn
Last Funding:
USD 44.3 mn (Seed; Aug 2021)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...

EDGE Insights

Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.